153 related articles for article (PubMed ID: 38302780)
1. Ki-67 Change in Anthracyline-containing Neoadjuvant Chemotherapy Response in Breast Cancer.
Yang ZG; Ren LH; Wang F; Wang PL; Wang WY; Lin SY
Curr Med Sci; 2024 Feb; 44(1):156-167. PubMed ID: 38302780
[TBL] [Abstract][Full Text] [Related]
2. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
3. Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in breast cancer.
Qin Q; Gao F; Jiang W; Tan Q; Mo Q; Wei C
Chin Med J (Engl); 2014; 127(18):3272-7. PubMed ID: 25266526
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
Chen R; Ye Y; Yang C; Peng Y; Zong B; Qu F; Tang Z; Wang Y; Su X; Li H; Yang G; Liu S
Breast Cancer Res Treat; 2018 Jul; 170(1):35-43. PubMed ID: 29480449
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A
Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438
[TBL] [Abstract][Full Text] [Related]
6. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Yao L; Liu Y; Li Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2011 Jun; 22(6):1326-1331. PubMed ID: 21196440
[TBL] [Abstract][Full Text] [Related]
7. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
8. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
10. [Association between hormone receptors and response to neoadjuvant anthracycline-based chemotherapy in breast cancer patients].
Wei Y; Li JF; Wang TF; Xie YT; Fan ZQ; Fan T; Lu AP; Ouyang T; Lin BY
Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Oct; 39(5):481-3. PubMed ID: 17940564
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
[TBL] [Abstract][Full Text] [Related]
12. Association of Menopausal Status, Expression of Progesterone Receptor and Ki67 to the Clinical Response to Neoadjuvant Chemotherapy in Luminal Breast Cancer.
Silva LRD; Vargas RF; Shinzato JY; Derchain SFM; Ramalho S; Zeferino LC
Rev Bras Ginecol Obstet; 2019 Dec; 41(12):710-717. PubMed ID: 31856290
[TBL] [Abstract][Full Text] [Related]
13. Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy.
Cabrera-Galeana P; Muñoz-Montaño W; Lara-Medina F; Alvarado-Miranda A; Pérez-Sánchez V; Villarreal-Garza C; Quintero RM; Porras-Reyes F; Bargallo-Rocha E; Del Carmen I; Mohar A; Arrieta O
Oncologist; 2018 Jun; 23(6):670-678. PubMed ID: 29490940
[TBL] [Abstract][Full Text] [Related]
14. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
[TBL] [Abstract][Full Text] [Related]
15. Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy.
Tan S; Fu X; Xu S; Qiu P; Lv Z; Xu Y; Zhang Q
Pathol Oncol Res; 2021; 27():1609972. PubMed ID: 34987312
[No Abstract] [Full Text] [Related]
16. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
17. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
[TBL] [Abstract][Full Text] [Related]
19. High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Alba E; Lluch A; Ribelles N; Anton-Torres A; Sanchez-Rovira P; Albanell J; Calvo L; García-Asenjo JA; Palacios J; Chacon JI; Ruiz A; De la Haba-Rodriguez J; Segui-Palmer MA; Cirauqui B; Margeli M; Plazaola A; Barnadas A; Casas M; Caballero R; Carrasco E; Rojo F
Oncologist; 2016 Feb; 21(2):150-5. PubMed ID: 26786263
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer.
Burcombe RJ; Makris A; Richman PI; Daley FM; Noble S; Pittam M; Wright D; Allen SA; Dove J; Wilson GD
Br J Cancer; 2005 Jan; 92(1):147-55. PubMed ID: 15611798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]